New Methods Of Treatment Parkinson's Disease

New Methods Of Treatment Parkinson's Disease.

Parkinson's contagion has no cure, but three hypothetical treatments may help patients cope with unpleasant symptoms and related problems, according to revitalized research. The research findings will be presented at the annual meeting of the American Academy of Neurology in San Diego from March 16 to 23, 2013. "Progress is being made to increase our use of medications, expatiate new medications and to treat symptoms that either we haven't been able to treat effectively or we didn't earn were problems for patients," said Dr Robert Hauser, professor of neurology and supervisor of the University of South Florida Parkinson's Disease and Movement Disorders Center in Tampa Parkinson's disease, a degenerative sense disorder, affects more than 1 million Americans.

It destroys audacity cells in the brain that make dopamine, which helps control muscle movement. Patients occurrence shaking or tremors, slowness of movement, balance problems and a stiffness or rigidity in arms and legs. In one study, Hauser evaluated the medicine droxidopa, which is not yet approved for use in the United States, to relief patients who experience a rapid fall in blood pressure when they stand up, which causes light-headedness and dizziness sildenafil napifit. About one-fifth of Parkinson's patients have this problem, which is due to a dead duck of the autonomic nervous routine to release enough of the hormone norepinephrine when posture changes.

Hauser studied 225 people with this blood-pressure problem, assigning half to a placebo put together and half to take droxidopa for 10 weeks. The pharmaceutical changes into norepinephrine in the body. Those on the medicine had a two-fold decline in dizziness and lightheadedness compared to the placebo group. They had fewer falls, too, although it was not a statistically significant decline.

In a double study, Hauser assessed 420 patients who adept a daily "wearing off" of the Parkinson's pharmaceutical levodopa, during which their symptoms didn't respond to the drug. He compared those who took contrasting doses of a new drug called tozadenant, which is not yet approved, with those who took a placebo.

All still took the levodopa. At the inception of the study, the patients had an average of six hours of "off time" a hour when symptoms reappeared. After 12 weeks, those on a 120-milligram or 180-milligram dose of tozadenant had about an hour less of "off time" each date than they had at the start of the study.

Tozadenant, which works on brain receptors thought to maintain motor function, merits further study in future trials, Hauser said. In another study, Hauser looked at 321 patients with initial stage Parkinson's whose symptoms weren't handled well by a c physic called a dopamine agonist, typically the first drug prescribed for Parkinson's patients. During the 18-week study, Hauser assigned them to understand either their usual medicine plus an add-on stupefy called rasagiline (brand name Azilect) or their usual medicine and a placebo.

Azilect is approved for use in patients with betimes stage disease as a single therapy or as an add-on to levodopa, Hauser said, but not yet as an add-on to dopamine agonists. Those taking the Azilect - but not those taking the placebo - improved by 2,4 points on a law Parkinson's blight rating scale. Costs of the still unapproved drugs are not known.

Azilect costs about $200 monthly at the 1-milligram quotidian dose used in the study. Each of the studies was funded by the pharmaceutical actors making the particular drug: Chelsea Therapeutics paid for the blood-pressure study; Biotie Therapies Inc, supported the "wearing-off" study; and Teva Pharmaceutical Industries sponsored the Azilect study. Hauser is a counselor for all three companies.

Most stirring of the three studies is the use of droxidopa to mitigate dizziness and fainting, said Dr Michael Okun, national medical director of the National Parkinson Foundation and overseer of the University of Florida Center for Movement Disorders and Neurorestoration. Drugs are already at one's fingertips to treat the problem, and compression stockings are also often recommended.

Even so, "having another drug in that arena is common to help a lot of people," he said. The effects of the other two treatments are more modest, said Okun, who is also a neurology professor. Additional studies will aide determine how noteworthy the effects are in valid life, he said hgh diabetes. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed medical journal.

tag : study patients parkinson hauser placebo azilect symptoms disease movement

Post a comment

Private comment



Welcome to FC2!

Latest journals
Latest comments
Latest trackbacks
Monthly archive
Search form
Display RSS link.
Friend request form

Want to be friends with this user.